First author [ref.] | Country | Setting | Period of data collection | Type and sample size | Inappropriate TB treatment | Data quality | |
SC | TR | ||||||
Wei [43] | Taiwan | In- and outpatients via tertiary care centre | 1995–2004 | Peripheral lymph-adenitis, n=97 | Assessed: 18% | * | * |
Llewelyn [45] | UK | General hospital | 1995–1998 | Pregnant females, n=13 | Assessed: 0% (all HRZE; although mix of patients) | * | ** |
O'Donnel [47] | Brazil | Hospital | 1997–1999 | AIDS patients, n=9 | Assessed: at least 33% | * | ** |
Kuzucu [42] | Turkey | Hospital | 1997–2002 | Chest wall, n=6 | Assessed: 0% | *** | *** |
Fennira [41] | Tunisia | Hospital | 1997–2003 | Vertebral, n=5 | Assessed: 0% | * | * |
Cormican [40] | UK | TB clinic | 1999–2004 | Spinal, n=22 | Assessed: 5% (n=1, no isoniazid) | * | * |
Fonseca [46] | Portugal | Hospital | 1999–2005 | TNF-α treated patients, n=13 | Assessed: 0% (all HRZE; although mix of patients) | * | ** |
Chang [50] | China | Governmental clinic | 2001 | Hepatotoxicity, n=47 | Assessed: insufficient information | ** | * |
Kim [44] | South Korea | Hospital | 2001–2005 | Isoniazid resistant, n=39 | Assessed: no guidelines for isoniazid resistant TB available in 2001–2005 | ** | *** |
Godreuil [48] | France | Clinical mycobacterial laboratories | 2002–2007 | Mycobacterium microti, n=6 | Assessed: 67% | *** | ** |
Kawasaki [49] | Japan | Hospital | 2005–2007 | Patients who died from TB, n=52 | Assessed: insufficient information | * | * |
SC: study characteristics; TR: treatment regimens; TNF: tumour necrosis factor; H: isoniazid; R: rifampicin; E: ethambutol; Z: pyrazinamide. *: low quality; **: moderate quality; ***: high quality.